Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Sep 26, 2014; 6(9): 939-958
Published online Sep 26, 2014. doi: 10.4330/wjc.v6.i9.939
miRNome in myocardial infarction: Future directions and perspective
Emanuela Boštjančič, Damjan Glavač
Emanuela Boštjančič, Damjan Glavač, Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
Author contributions: Boštjančič E wrote the paper; Glavač D revised the paper critically; Boštjančič E and Glavač D gave the final approval of the version to be published.
Correspondence to: Damjan Glavač, PhD, Professor of Human Genetics, Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenia. damjan.glavac@mf.uni-lj.si
Telephone: +386-1-5437180 Fax: +386-1-5437181
Received: December 29, 2013
Revised: June 23, 2014
Accepted: June 27, 2014
Published online: September 26, 2014
Core Tip

Core tip: MicroRNAs (miRNAs) contribute to various developmental, physiological and pathological processes in the heart. Cardiac diseases show abnormal miRNA regulation. Primary studies of miRNA involvement in cardiac disease analyzed mainly miRNAs that enriched in or specific for cardiomyocytes; however, growing evidence suggests that other cell-type-specific or ubiquitously expressed miRNAs are also involved in cardiovascular disease. miRNAs were found to contribute to the pathogenesis of myocardial infarction (MI) and post-MI. The majority of studies focused on miRNAs in animal models of MI, in human and animal plasma samples of MI (prognostic and diagnostic targets), and on miRNAs as promising therapeutic targets.